Delivery Order 75N95022D00012-75N95023F00001
Award Date 6/1/23
Potential Completion Date 5/31/24
Potential Value $830K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Austria
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services' National Institutes of Health National Institute on Aging awarded a $298,624 firm fixed-price purchase order to QPS Austria GmbH to provide phenotypic screening services to identify effective treatments for Alzheimer's disease. The requirement, as outlined in the solicitation, is for the contractor to test approximately 20 FDA-approved drugs that have been nominated as potential treatments in order to determine if exposure is associated with lower...
- This is a $199,812 firm fixed price purchase order awarded by the National Institutes of Health's (NIH) National Institute on Aging (NIA) to QPS Austria GMBH, a contract research organization. The contract is for in vivo efficacy studies of a candidate Alzheimer's treatment in a transgenic mouse model. This award is part of the NIA's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study, which aims to identify FDA-approved drugs that may be repurposed as disease-modifying...
- This is a firm fixed-price delivery order contract awarded by the National Institute on Aging (NIA), a civilian federal agency, to Scantox Neuro GMBH, a for-profit organization based in Austria. The contract, valued at $858,106.08, is for the experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. This work supports ongoing NIA research initiatives such as the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and PREVENT-AD studies....
- This is a $249,334 firm fixed-price purchase order awarded by the National Institute on Aging (NIA) to Scantox Neuro GMBH, a for-profit organization based in Austria. The contract supports pharmacodynamic and tolerability studies of candidate Alzheimer's disease (AD) drugs using a transgenic AD mouse model. This work builds on NIA's ongoing efforts under the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and Experimental Validation of Candidate Alzheimer's Disease Treatments...
- This federal contract award to Scantox Neuro GMBH, a for-profit organization based in Austria, is for $249,000.00 to conduct tolerability studies of candidate Alzheimer's disease (AD) drugs and evaluate the efficacy of poly(L-lysine succinylated)-hydroxychloroquine (PLS-HCQ) in a transgenic AD mouse model. The award is part of the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and Experimental Validation of Candidate Alzheimer's Disease Treatments Identified by Multi-Omics Analyses...
- This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Aging to the National University of Singapore. The $169,830 contract is for testing the efficacy of candidate Alzheimer's disease treatments in rescuing impaired hippocampal synaptic plasticity. This is part of the NIH's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study, which is testing approximately 20 FDA-approved drugs to...
- <p>The National Institutes of Health Office of Logistics and Acquisition Operations awarded a $1,499,309 delivery order contract to the National Academy of Sciences for priority-setting for prevention and treatment-related research on Alzheimer's disease and related dementias at the National Institutes of Health. The contract is cost-no-fee and will be performed in Washington, D.C. over a period of approximately two years, from March 2023 through March 2025.</p>
- The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded a $107,238.60 firm fixed price purchase order to Quanterix Corporation, a for-profit manufacturer, for Simoa 4-plex 96-well plate assays to quantify serum/plasma biomarkers for Alzheimer's disease research. The assays will be used to analyze samples from participants in the Baltimore Longitudinal Study of Aging and the Genetic and Epigenetic Signatures of Translational Aging Laboratory...
- This is a firm-fixed-price purchase order award to Alamar Biosciences, Inc. by the National Institute on Aging (NIA), a civilian agency, for $247,000.00. The contract is for providing proteomic analysis services, including the NULISAseq CNS Disease Panel 120 assay, next-generation sequencing, and bioinformatic support for 1,118 plasma samples. The purpose is to identify biomarkers that can be used to classify and stage Alzheimer's disease. This award is not associated with a set-aside and is the...
- The National Institutes of Health (NIH) Intramural Center for Alzheimer's and Related Dementias (CARD) awarded a $1,358,471.01 firm-fixed-price purchase order to Government Scientific Source Inc. for a High-Content Screening System (Opera Phenix Plus or equivalent). This equipment will support the Induced Pluripotent Stem Cell Neurodegenerative Disease Initiative (iNDI) project, which aims to measure how neurodegeneration-related mutations alter protein networks in disease-relevant cell...